Analyst Expectations For Dianthus Therapeutics's Future
Analysts have recently provided varied ratings for Dianthus Therapeutics (NASDAQ:DNTH), with an average 12-month price target of $62.25, reflecting a 15.28% increase from the previous target. Key analysts have raised their ratings, with Guggenheim setting a target of $100.00. Despite these positive outlooks, the company faces significant revenue challenges, with a decline of approximately -89.64% over the past three months and a net margin of -16388.08%. Dianthus Therapeutics is focused on developing novel monoclonal antibodies for severe autoimmune diseases.
In the preceding three months, 4 analysts have released ratings for Dianthus Therapeutics (NASDAQ:DNTH), presenting a wide array of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 2 | 0 | 0 | 0 |
| Last 30D | 1 | 1 | 0 | 0 | 0 |
| 1M Ago | 1 | 1 | 0 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
In the assessment of 12-month price targets, analysts unveil insights for Dianthus Therapeutics, presenting an average target of $62.25, a high estimate of $100.00, and a low estimate of $40.00. This current average has increased by 15.28% from the previous average price target of $54.00.
Interpreting Analyst Ratings: A Closer Look
In examining recent analyst actions, we gain insights into how financial experts perceive Dianthus Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Yatin Suneja | Guggenheim | Raises | Buy | $100.00 | $92.00 |
| Joel Beatty | Baird | Raises | Outperform | $67.00 | $50.00 |
| Swayampakula Ramakanth | HC Wainwright & Co. | Maintains | Buy | $40.00 | $40.00 |
| Laura Chico | Wedbush | Raises | Outperform | $42.00 | $34.00 |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Dianthus Therapeutics. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Dianthus Therapeutics compared to the broader market.
- Price Targets: Gaining insights, analysts provide estimates for the future value of Dianthus Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.
To gain a panoramic view of Dianthus Therapeutics's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
Stay up to date on Dianthus Therapeutics analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
About Dianthus Therapeutics
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.
Key Indicators: Dianthus Therapeutics's Financial Health
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Challenges: Dianthus Therapeutics's revenue growth over 3M faced difficulties. As of 30 June, 2025, the company experienced a decline of approximately -89.64%. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Dianthus Therapeutics's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -16388.08%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Dianthus Therapeutics's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -10.01%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Dianthus Therapeutics's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -9.38%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Dianthus Therapeutics's debt-to-equity ratio is below the industry average. With a ratio of 0.0, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
The Basics of Analyst Ratings
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
